2-(4-carbamoylphenoxy)-ethyl chloride | 36616-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-carbamoylphenoxy)-ethyl chloride
• 英文别名: 4-(2-chloroethoxy)benzamide；2-(4-carbamoylphenoxy) ethyl chloride
• CAS: 36616-30-5
• 化学式: C₉H₁₀ClNO₂
• mdl: MFCD11164785
• 分子量: 199.637
• InChiKey: CVQWYCCXJPYZQI-UHFFFAOYSA-N

物化性质

• 沸点：
  358.9±17.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-carbamoylphenoxy)-ethyl chloride 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.67h， 生成 N-acetyl-4-<2-(1H-imidazol-1-yl)ethoxy>benzamide
  参考文献：
  名称：

  Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles

  摘要：

  1-(2-Phenoxyethyl)-1H-imidazole was found to be an inhibitor of thromboxane (TxA2) synthetase, but it also inhibited the adrenal cytochrome P-450 enzyme steroid 11 beta-hydroxylase. The preparation of a series of analogues is described, and activity against TxA2 synthetase, PGI2 synthetase, cyclooxygenase, and steroid 11 beta-hydroxylase is discussed. Potency against TxA2 synthetase was increased by introduction of a carboxyl group at a suitable distance from the imidazole ring. A distance of 8.1-8.8 A between N-1 of the imidazole and the carboxyl carbon was found to be optimal. Introduction of a carboxyl group also had the effect of reducing activity against steroid 11 beta-hydroxylase. The most potent and selective compound was found to be 4-[2-(1H-imidazol-1-yl) ethoxy]benzoic acid (14).

  DOI：

  10.1021/jm00148a009
• 作为产物：
  描述：

  4-羟基苯甲酰胺 、 苯磺酸2-氯乙酯 在 potassium carbonate 作用下， 以 水 、 丁酮 为溶剂， 生成 2-(4-carbamoylphenoxy)-ethyl chloride
  参考文献：
  名称：

  Anti-arrhythmic agents

  摘要：

  一系列具有抗心律失常药物作用的[N-烷基-N-(硝基、烷基磺酰胺基或氨基苯基)氨基]-烷基、烷氧基或烷基硫基苯基衍生物。

  公开号：

  US04959366A1

文献信息

• N-(phenoxyalkyl)imidazoles as selective inhibitors of the thromboxane
  申请人：Pfizer Inc.

  公开号：US04602016A1

  公开（公告）日：1986-07-22

  N-(mono or disubstituted phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis, migraine, and the vascular complications of diabetes.

  N-(单取代或双取代苯氧烷基)咪唑及其药用可接受的酸盐能够选择性地抑制血栓素合成酶酶的作用，而不显著抑制前列环素合成酶或环氧化酶酶的作用，因此在缺血性心脏病、中风、短暂性缺血发作、血栓形成、偏头痛以及糖尿病的血管并发症治疗中是有用的。
• Method of stimulating the heart employing ureido substituted
  申请人：Pfizer Inc.

  公开号：US03976783A1

  公开（公告）日：1976-08-24

  Method of stimulating the heart employing substituted 1-phenyl-2-alkylamino-alkanols, 1-phenyl-2-alkylamino-alkanes and .alpha.-aminoalkyl phenyl ketones is disclosed.

  揭示了一种利用取代的1-苯基-2-烷基氨基-烷醇、1-苯基-2-烷基氨基-烷烃和α-氨基烷基苯酮来刺激心脏的方法。
• Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses
  申请人：Celanire Sylvain

  公开号：US20080275046A1

  公开（公告）日：2008-11-06

  The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H 3 -receptor ligands, Formula (I), wherein, A 1 is CH, C(alkyl), C-halogen or N; R 1 is hydrogen, halogen, C 1-6 alkyl or alkoxy; R 2 is, Formula (II′), A 3 is O or S; R 3 is hydrogen, halogen, C 1-6 alkyl or alkoxy; R 4 is hydrogen, halogen, C 1-6 alkyl, alkoxy or —O-L; R 5 is hydrogen or —O-L, wherein L is an aminoalkyl group and at least one of R 4 and R 5 should be —O-L.

  本发明涉及一种包含氧唑或噻唑基团的化合物，其化学式为(I)，以及制备它们的方法、包含该化合物的药物组合物以及其作为H3受体配体的用途，式(I)中，A1为CH、C(烷基)、C-卤或N；R1为氢、卤素、C1-6烷基或烷氧基；R2为式(II')、A3为O或S；R3为氢、卤素、C1-6烷基或烷氧基；R4为氢、卤素、C1-6烷基、烷氧基或-O-L；R5为氢或-O-L，其中L为氨基烷基团，且R4和R5中至少有一个应为-O-L。
• DE2135678
  申请人：——

  公开号：——

  公开（公告）日：——
• N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor
  申请人：Pfizer Limited

  公开号：EP0245997B1

  公开（公告）日：1992-04-15